Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levofloxacin + rifapentine
- Development stage
- Preclinical
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antibiotic therapy consisting of levofloxacin (a fluoroquinolone antibiotic) and rifapentine (a rifamycin derivative). This combination provides complementary mechanisms of action against bacterial pathogens, particularly Mycobacterium tuberculosis. The combination has shown efficacy in treating pulmonary tuberculosis and other bacterial infections by effectively regulating immune functions and inhibiting inflammatory reactions.
02
Targets
Topo IV (Bacterial Topoisomerase IV)DNA gyraseRNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on levofloxacin + rifapentine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levofloxacin + rifapentine.